GlassScriptPhysician profile
James Y Lin
NPI 1881789600
$21,370.21
in general payments reported to CMS, 2019-2025
44 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,359 · 2020: $1,672 · 2021: $4,520 · 2022: $3,490 · 2023: $3,900 · 2024: $2,987 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,310 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14.92 · Travel and Lodging: $3.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,310.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14.92 |
| Travel and Lodging | $3.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,441.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,168.29 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,867.64 | 2019-2025 | Repatha, Evenity, Prolia |
| Abbvie INC. | $1,728.07 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,260.95 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $1,102.08 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $951.02 | 2019-2025 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $917.78 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $809.05 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $650.27 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $586.03 | 2023-2025 | Austedo Xr, Austedo Xr |
| Merck Sharp & Dohme LLC | $564.24 | 2019-2024 | Steglatro, Belsomra, Gardasil 9 |
| Pfizer INC. | $530.73 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $502.90 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $355.34 | 2023-2025 | Rexulti, Nuedexta |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $345.79 | 2019-2025 | Tymlos |
| Allergan, INC. | $303.63 | 2019-2020 | |
| Eisai INC. | $250.00 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $249.97 | 2024 | |
| Alkermes, INC. | $245.00 | 2021-2022 | |
| Vivus LLC | $245.00 | 2024-2025 | Pancreaze |
| Cmp Pharma, INC. | $237.31 | 2023 | Norliqva |
| Biohaven Pharmaceuticals, INC. | $234.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.04 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $178.99 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.41 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $155.86 | 2024-2025 | General - Pain Management |
| Mannkind Corporation | $124.51 | 2023 | V-Go |
| Abbott Laboratories | $124.09 | 2019 | |
| Exact Sciences Corporation | $121.69 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $112.57 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $86.43 | 2021 | |
| Arbor Pharmaceuticals, INC. | $75.66 | 2020-2022 | |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Seqirus USA INC | $60.27 | 2023-2024 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Avanir Pharmaceuticals, INC. | $46.29 | 2021 | |
| Medicure Pharma INC. | $44.46 | 2022-2024 | Zypitamag |
| Sanofi Pasteur INC. | $44.46 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $43.08 | 2019 | |
| Gilead Sciences, INC. | $36.47 | 2020-2021 | |
| Verona Pharma, INC. | $30.03 | 2025 | Ohtuvayre |
| Ipsen Biopharmaceuticals, INC | $29.67 | 2023 | Dysport |
| Lundbeck LLC | $20.51 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $18.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.